Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy CEO Says Purchase By Daiichi Not Threatened By Investigation

This article was originally published in PharmAsia News

Executive Summary

The acquisition of Ranbaxy Laboratories by Daiichi Sankyo is still on track and cannot legally be derailed, according to the Indian firm's CEO. Malvinder Singh said his counterparts at Daiichi were aware the U.S. FDA had questions about some of Ranbaxy's generic drugs before the agency's investigation became public. Singh addressed a news conference in the wake of speculation the merger of the two giants might be scuttled by FDA's questions. He said there was no doubt the $4.6 billion deal was still alive. Daiichi confirmed the sale is final. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel